Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18260175 | 1.00 | FFAR1 (0.36) | FFAR1ERN1GRM5PTPN1ALDH1A1 | |
| SCHEMBL18260214 | 0.76 | ALDH1A1 (0.43) | FFAR1PTPN1ALDH1A1HPGDRAB9A | |
| SCHEMBL18260217 | 0.76 | ALDH1A1 (0.43) | FFAR1PTPN1ALDH1A1HPGDRAB9A | |
| SCHEMBL15896161 | 0.76 | ERN1 (0.47) | FFAR1ERN1GRM5ALDH1A1HPGD | |
| SCHEMBL30864329 | 0.76 | ERN1 (0.47) | FFAR1ERN1GRM5ALDH1A1HPGD | |
| SCHEMBL18260229 | 0.75 | FFAR1 (0.42) | FFAR1GRM5PTPN1ALDH1A1PTGER1 | |
| SCHEMBL18260231 | 0.75 | FFAR1 (0.42) | FFAR1GRM5PTPN1ALDH1A1PTGER1 | |
| SCHEMBL18260205 | 0.72 | CA12 (0.43) | FFAR1GRM5ALDH1A1HPGD | |
| SCHEMBL18260203 | 0.72 | CA12 (0.43) | FFAR1GRM5ALDH1A1HPGD | |
| SCHEMBL18260227 | 0.72 | TSHR (0.34) | FFAR1PTPN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708351-B2 | Alkenes as alkyne equivalents in radical cascades terminated by fragmentations | The Florida State University Research Foundation, Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708351-B2 | Alkenes as alkyne equivalents in radical cascades terminated by fragmentations | The Florida State University Research Foundation, Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708351-B2 | Alkenes as alkyne equivalents in radical cascades terminated by fragmentations | The Florida State University Research Foundation, Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | The Florida State University Research Foundation, Inc. | 2016-12-01 | — | — | US | disclosed |
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | The Florida State University Research Foundation, Inc. | 2016-12-01 | — | — | US | disclosed |
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | The Florida State University Research Foundation, Inc. | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347778-A1 | ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS | AOC3, OR51E2, AOC2 | FFAR1 1842/4885ERN1 1009/4885GRM5 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.